Breast Cancer Research and Treatment

, Volume 38, Issue 1, pp 57–66

The significance ofheregulin in breast cancer tumor progression and drug resistance

  • R. Lupu
  • M. Cardillo
  • C. Cho
  • L. Harris
  • M. Hijazi
  • C. Perez
  • K. Rosenberg
  • D. Yang
  • C. Tang
Tumor growth pathways and their inhibition


TheerbB-2 receptor plays an important role in the prognosis of breast cancer and is expressed at high levels in nearly 30% of tumors in breast cancer patients. While evidence accumulates to support the relationship betweenerbB-2 overexpression and poor overall survival in human breast cancer, understanding of the biological consequence(s) oferbB-2 overexpression remains elusive. The discovery ofheregulin has allowed us to identify a number of related but distinct biological endpoints which appear responsive to signal transduction through theerbB-2/4 receptor. These endpoints of growth, invasiveness, and differentiation have clear implications for the emergence, maintenance, and/or control of malignancy, and represent established endpoints in the assessment of malignant progression in human breast cancer. Preliminary studiesin vitro have shown thatheregulin induces a biphasic growth effect on cells witherbB-2 overexpression. Interestingly, we observed that expression ofheregulin correlates with a more aggressive/invasive, vimentin-positive phenotype in breast cancer cells lines. Therefore, we have postulated thatheregulin is involved in breast cancer tumor progression. We have shown thatheregulin inducesin vitro chemoinvasion and chemotaxis of breast cancer cells as well as growth in an anchorage dependent and independent manner. Interestingly, aheregulin neutralizing antibody inhibits chemotaxis and results in cell growth inhibition and blockade of the invasive phenotype. Strikingly, genetically engineered cells which constitutively expressheregulin demonstrate critical phenotypic changes that are associated with a more aggressive phenotype. Specifically, these cells are no longer dependent on estrogen for growth and are resistant to tamoxifenin vitro andin vivo, and moreover these cells metastasize to lymph nodes in athymic nude mice. These tumors appear to have lostbcl-2 expression as compared with the control tumors. In addition, presumably by activation/regulation of topoisomerase II, theheregulin-transfected cells become exquisitely sensitive to doxorubicin and VP-16. Clearly, mechanistic aspects of theerbB-2/4 andheregulin interaction need to be understood from a therapeutic standpoint which could provide additional insights into synergistic treatments for certain patients, or improve treatment regimens for a large number of women. The study ofheregulin and its co-expression witherbB-2/4 receptor and the assessment of its involvement in the progression from the in situ stage of breast tumors to the invasive one will additionally increase the relevance ofheregulin as a prognostic/diagnostic factor. We believe that our studies provide new insights into breast cancer diagnosis, prognosis, and treatment.

Key words

EGF receptor family erbB-2 erbB-4 heregulin differentiation invasiveness proliferation estrogen dependence drug resistance prognosis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Henderson I, Harris J, Kinne D, Hellman S:In: De Vita V, Hellman S (eds) Principles and Practice of Oncology. Lippincott, Philadelphia, 1989, pp 1197–1268Google Scholar
  2. 2.
    Schecter AL, Stern DF, Vaidyanathan L, Decker SJ: The neu oncogene: an erbB-related gene encoding a 185,000 Mr tumor antigen. Nature 312:513–516, 1984PubMedGoogle Scholar
  3. 3.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human BC: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987PubMedGoogle Scholar
  4. 4.
    Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R:neu-protein overexpression in breast cancer. Association with comedotype ductal carcinomain situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239–1245, 1988PubMedGoogle Scholar
  5. 5.
    Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H: ErbB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137–143, 1991PubMedGoogle Scholar
  6. 6.
    Nicholson S, Wright C, Sainsbury RC, Halcrow P, Kelly P, Angus B, Farndon JR, Harris AL: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Molec Biol 37:811–814, 1990PubMedGoogle Scholar
  7. 7.
    Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeberg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with the neu oncogene. Science 230:1132–1139, 1985PubMedGoogle Scholar
  8. 8.
    Fukushige SI, Matsubaru K, Yoshida M: Localization of a novel v-erbB-related gene, c-erbB-2, on chromosome 17 and its amplification in a gastric cell line. Mol Cell Biol 6:955–958, 1986PubMedGoogle Scholar
  9. 9.
    Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 319:230–234, 1986PubMedGoogle Scholar
  10. 10.
    Semba K, Kamata N, Toyoshima K, Yamamoto T: v-erbB related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Aci USA 82:6497–6501, 1985Google Scholar
  11. 11.
    Muller W, Sinn E, Patengale P, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115, 1988PubMedGoogle Scholar
  12. 12.
    Bouchard L, Lamarre L, Tremblay P, Jolicoeur P: Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931–936, 1989PubMedGoogle Scholar
  13. 13.
    Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178–182, 1986Google Scholar
  14. 14.
    Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p 185 (HER2) causes transformation and tumorigenesis of NIH3T3 cells. Proc Natl Acad Sci USA 84: 7159–7163, 1987PubMedGoogle Scholar
  15. 15.
    Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger, Lippman ME, King CR: Pathological findings from National Surgical Adjuvant Breast Project (protocol B-06), prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112, 1990PubMedGoogle Scholar
  16. 16.
    Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49:2087–2090, 1989PubMedGoogle Scholar
  17. 17.
    Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1988Google Scholar
  18. 18.
    Shih C, Padhy L, Murray M, Weinberg RA: Transforming genes of carcinoma and neuroblastomas introduced into mouse fibroblasts. Nature 290:261–264, 1981PubMedGoogle Scholar
  19. 19.
    Bargmann CI, Hung MC, Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230, 1986PubMedGoogle Scholar
  20. 20.
    Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA: Different structural alterations upregulatein vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8:5570–5574, 1988PubMedGoogle Scholar
  21. 21.
    Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against c-erbB-2 protein enhances the cytotoxicity of cis-diammine dichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575–4580, 1991PubMedGoogle Scholar
  22. 22.
    Wiltschke C, Tyl E, Steininger A, Zielinski C, Spona J, Zeilinger R, Kury F, Czerwenka K, Kubista E, Speiser P, Preis P: Increased NK-cell activity correlates with low or negative expression of the HER-2/neu oncogene in breast cancer patients. Proc AACR 32:203, 1991Google Scholar
  23. 23.
    Read LD, Keith D Jr, Slamon DJ, Katzenellenbogen BS: Hormonal modulation of HER-2/neu proto-oncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 50:3947–3951, 1990PubMedGoogle Scholar
  24. 24.
    Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M: Inhibition of c-erbB-2 oncogene expression by estrogens in human.breast cancer cells. Oncogene 5:1001–1006, 1990PubMedGoogle Scholar
  25. 25.
    Lupu R, Wellstein A, Sheridan J, Ennis BW, Zugmaier G, Katz D, Lippman ME, Dickson RB: Purification and characterization of a novel growth factor from human breast cancer cells. Biochem 31:7330–7340, 1992Google Scholar
  26. 26.
    Lupu R, Colomer R, Zugmaier G, Shepard M, Slamon D, Lippman ME: Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB-2. Science 249:1552–1555, 1990PubMedGoogle Scholar
  27. 27.
    Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M: Ligand-specific activation of HER4/p180erbB-4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90:1746–1750, 1993PubMedGoogle Scholar
  28. 28.
    Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S:Heregulin induces tyrosine-phosphorylation of HER4/p180erbB-4. Nature 366:473–475, 1993PubMedGoogle Scholar
  29. 29.
    Lupu R, Colomer R, Kannan B, Lippman ME: Characterization of a growth factor binds exclusively to theerbB-2 receptor and induces cellular responses. Proc Natl Acad Sci USA 89:2287–2291, 1992PubMedGoogle Scholar
  30. 30.
    Lupu R, Lippman ME: The role oferbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res Treat 27:83–93, 1993PubMedGoogle Scholar
  31. 31.
    Huang SS, Huang JS: Purification and characterization of the neu/erbB2 ligand-growth factor from bovine kidney. J Biol Chem 267:11508–11512, 1992PubMedGoogle Scholar
  32. 32.
    Wen D, Peles E, Cupples R, Suggs SV, Bacus S, Lou Y, Trail G, Hu S, Silbiger SM, Ben Levi R, Koski R, Lu HS, Yarden Y: Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69:559–572, 1992PubMedGoogle Scholar
  33. 33.
    Holmes W, Sliwkowski MX, Akita RW, Henzel W, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD, Shepard MH, Kuang WJ, Wood WI, Goeddel DV, Vandlen RL: Identification of heregulin, a specific activator of p185erbB2. Science 256:1205–1210, 1992PubMedGoogle Scholar
  34. 34.
    Sommers CL, Thompson EW, Torri JA, Kemler R, Gelman EP, Byers SW: Cell adhesion molecule uvomorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth Differentiation 2:365–372, 1991PubMedGoogle Scholar
  35. 35.
    Staebler A, Sommers C, Mueller SC, Bayers S, Thompson EW, Lupu R: Modulation of breast cancer progression and differentiation by the gp30/heregulin. Breast Cancer Res Treat 31:175–182, 1994PubMedGoogle Scholar
  36. 36.
    Hijazi MM, Mueller SC, Torri J, Coopman P, Lupu R, Thompson EW: Gp30/Heregulin promotes invasive behavior and phenotype in SKBR3 cells and is blocked by gp30 polyclonal antiserum. Clinical & Experimental Metastasis, Vol 12, 5th Int Congress MRS, Abstract 69, 1994Google Scholar
  37. 37.
    Bacus SS, Huberman E, Chin D, Kiguchi K, Simpson S, Lippman ME, Lupu R: A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells. Cell Growth Differentiation 3:401–411, 1992PubMedGoogle Scholar
  38. 38.
    Muss HB, Thor A, Berry DA, Kute T, et al:erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 5:1260–1266, 1994Google Scholar
  39. 39.
    Allred DC, Clark GM, Tandon AK, Molina R, et al: HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence ofin situ carcinoma. J Clin Oncol 10:599–605, 1992PubMedGoogle Scholar
  40. 40.
    Gusterson BA, Gelber RD, Goldhirsh A, Price KN, et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10:1049–1056, 1992PubMedGoogle Scholar
  41. 41.
    Matsumura K, Isola J, Chew K, Henderson C, Smith HS, Harris AL, Hickson ID, Waldman F: Topoisomerase II alpha deletion as well as amplification associated witherbB-2 amplification in breast cancer. Proc AACR 35:454, 1994Google Scholar
  42. 42.
    Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL: Topoisomerase II alpha co-amplification witherbB-2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933–938, 1993PubMedGoogle Scholar
  43. 43.
    Kim R, Hirabayashi N, Nishiyama M, Saeki S, Toge T, Okada K: Expression of MDR1, GST-pi and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Research 11:429–431, 1991PubMedGoogle Scholar
  44. 44.
    Lemoine NR, Sikora K: Interventional genetics and cancer treatment. Brit Med J 306:6390–6393, 1993Google Scholar
  45. 45.
    Tang C, Cardillo M, Yang D, Cho C, Waibel C, Perez C, Lupu R:Heregulin β2 isoform can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Proc AACR 36:169, 1995Google Scholar
  46. 46.
    Tang C, Perez C, Grunt T, Lupu R: Biological characterization of an erbB-2 ligand: involvement of human breast cancer from a hormone dependent to hormone independent phenotype. Proc AACR 35:36, 1994Google Scholar
  47. 47.
    Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN: A rapidin vitro assay for quantitating the invasive potential of tumor cells. Cancer Research 47:3239–3245, 1987PubMedGoogle Scholar
  48. 48.
    Hijazi MM, Lupu R:Heregulin/gp30 polyclonal antibody inhibits invasive behavior in MDA-MB-231 breast cancer cells. Proc AACR 36:75, 1995Google Scholar
  49. 49.
    Tryggvason K: Patterns of basement degradation by metastatic tumor cell enzymes.In: Lapis K, Liotta LA, Rabson AS (eds) Biochemistry and Molecular Genetics of Cancer Metastasis. Martinus Nijhoff Publ, Boston, pp 151–163Google Scholar
  50. 50.
    Russell KS, Hung MC: Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor. Cancer Res 52:6624–6629, 1992PubMedGoogle Scholar
  51. 51.
    Cardillo M, Tang C, Lupu R:Heregulin induces a metastatic phenotype to breast cancer cells in vivo. Proc AACR 36:262, 1995Google Scholar
  52. 52.
    Harris LN, Tang C, Yang D, Lupu R: Induction of chemotherapy sensitivity in MCF-7 breast cancer cells byheregulin. Proc AACR 36:426, 1995Google Scholar
  53. 53.
    Harris LN, Tang C, Perez C, Lupu R: Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with gp-30 (heregulin), an activator of theerbB-2/erbB-4 signalling pathway. Fifth Meeting on the Molecular Basis of Cancer, June 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • R. Lupu
    • 1
  • M. Cardillo
    • 1
  • C. Cho
    • 1
  • L. Harris
    • 1
  • M. Hijazi
    • 1
  • C. Perez
    • 1
  • K. Rosenberg
    • 1
  • D. Yang
    • 1
  • C. Tang
    • 1
  1. 1.Vincent T. Lombardi Cancer Research CenterGeorgetown University Medical CenterWashington DCUSA
  2. 2.Lombardi Cancer Research CenterGeorgetown University Medical CenterWashington DCUSA

Personalised recommendations